Oxaliplatin-induced allergic reaction in patients with colorectal cancer in Japan
- 236 Downloads
Oxaliplatin is a platinum compound that is clinically effective for colorectal cancer (CRC), in combination with 5-fluorouracil (5-FU) and leucovorin (LV), and it is widely used for metastatic disease and for the adjuvant treatment of stage III CRC. With the increasing use of oxaliplatin in Japan, serious adverse events have been experienced other than hematologic and neurologic toxicities.
In order to clarify the clinical features of allergic reactions to oxaliplatin, we retrospectively investigated CRC patients who had received oxaliplatin-based chemotherapies.
One hundred and twenty-five CRC patients who had been treated with FOLFOX regimens (containing oxaliplatin, 5-FU, and LV) were examined, and 21 patients (17%) were found to have developed allergic reactions. Sixteen patients (13%) had grade 1/2 adverse events, classified according to the common terminology criteria for adverse events (CTC-AE) version 3.0 and 5 (4%) had grade 3/4 adverse events. The allergic reaction appeared after a median number of nine cycles (range, 2–15 cycles). Previous chemotherapy included 5-FU/LV, CPT-11, and S-1. All of the patients with allergic reactions recovered completely when treated with antiallergy drugs. Oxaliplatin was reintroduced in 11 patients, with the use of prophylactic agents; allergic reaction to the reintroduction was not observed in 8 patients and grade 1/2 allergic reactions developed in 3 patients. No correlation was identified between allergic reaction and patients’ background characteristics such as sex, history of allergy, and profile of other adverse events.
Allergic reactions to oxaliplatin remain an important issue for patients being able to safely continue effective chemotherapies; further analysis will be needed to establish methods for the prediction and prophylaxis of such reactions.
Key wordsColorectal cancer Oxaliplatin Allergic reaction
- 2.Goldberg RM, Sargent D, Morton RF, et al. (2004) N9741: FOLFOX (oxaliplatin (Oxal)/5-FU/leukovorin (LV)) or reduced dose R-Ifl(CPT-11 + 5-FU/LV) in advanced colorectal cancer (CRC): final efficacy data from an Intergroup Study. J Clin Oncol 23:275 (Suppl; abstract 3621)Google Scholar
- 4.Andre T, Boni C, Mounedji-Boudiaf L, et al. (2004) Multicenter international study of oxaliplatin/5-fluorouracil/leukovorin in the adjuvant treatment of colon cancer (MOSAIC) investigators: oxaliplatin, fluorouracil and leukovorin as adjuvant treatment for colon cancer. N Engl J Med 50:2243–2251Google Scholar
- 6.Siu SW, Chan RT, Au GK (2006) Hypersensitivity reactions to oxaliplatin:experience in a single institute. Ann Oncol 17:2590–2261Google Scholar
- 19.Markmen M, Kennedy A, Webster K, et al. (1999) Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol 17: 1141–1145Google Scholar